Neurogene stops Batten gene therapy after FDA denies request, dealing double dose of bad news Read more 

Incyte's $750M buyout rocked by pause on key trial, asset cull Read more 

Nearing potential FDA approval, BridgeBio shows additional positive data on ATTR-CM candidate acoramidis Read more 

The Cambridge Rare Disease Showcase

This annual event serves as a celebration of the innovative work and compelling narratives emerging from the rare disease community. It is designed to bring [...]

Go to Top